Karen highlights the struggles of navigating corporate environments, particularly in the pharmaceutical industry, where consensus is crucial. She shares her experience of being silenced when raising concerns about liability and technology, emphasizing the lack of open dialogue and the consequences of dissent. The conversation sheds light on the complexities of accountability within large organizations.
